Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884265 | 0.86 | ALDH1A1 (0.39) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL2882168 | 0.84 | RAB9A (0.43) | CDK2 | |
| SCHEMBL2881754 | 0.79 | MAPT (0.39) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL2880067 | 0.75 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL2213284 | 0.66 | NPC1 (0.38) | — | |
| SCHEMBL2877011 | 0.63 | ALDH1A1 (0.41) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL2877008 | 0.62 | KDM4E (0.43) | CDK2 | |
| SCHEMBL31351818 | 0.61 | KDM4E (0.52) | CDK2CHEK1CCNA2CCNA1 | |
| SCHEMBL2212035 | 0.60 | SMN1; SMN2 (0.39) | CDK2CCNE1 | |
| SCHEMBL2213285 | 0.59 | MAPK14 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745446-B2 | Pyrazolo[1,5-c]pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-29 | — | — | US | disclosed |
| US-20070254046-A1 | Novel Pyrazolopyrimidines | ALTANA PHARMA AG (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254046-A1 | Novel Pyrazolopyrimidines | MCL1, RARS2, CDK4 | CDK2 8/4885CHEK1 72/4885CCNA2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.